20 Future Swiss HealthTech and MedTech Leaders

Nelson Advisors
3 hours ago
13 min read

The Macroeconomic and Academic Foundations of Swiss Innovation

The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital influx, the medtech and biotech sectors have emerged as the most resilient pillars, driven by the unparalleled efficiency of the Swiss academic engine, specifically the Swiss Federal Institutes of Technology in Zurich (ETH Zurich) and Lausanne (EPFL).

The record-breaking creation of 46 new ventures from ETH Zurich in 2025 serves as a testament to the maturation of the university spin-off model. This model is no longer merely about patent licensing but represents a comprehensive institutional commitment to commercializing research through formalized pathways like the ETH Pioneer Fellowship and the newly launched "Express Licensing" procedure. This procedure, which provides a standardized, negotiation-free license within six to eight weeks in exchange for a modest 2% equity stake, has drastically reduced the barriers to entry for scientific founders. Consequently, Swiss academic institutions now rank among the top ten globally for spin-off value creation, outperforming larger economies on a per-capita basis.

However, the ecosystem faces a structural "late-stage gap," where approximately 96% of late-stage capital originates from international sources. This has necessitated a strategic focus on global expansion, particularly into the United States market. The Venture Leaders Medtech program, which selects the "Swiss National Startup Team" for an intensive roadshow in Boston, serves as a critical bridge for these 20 leaders as they transition from pre-clinical prototypes to market-ready clinical solutions.

Comparative VC Funding Landscape 2025

The following data illustrates Switzerland's leading position in venture capital efficiency relative to its European peers, highlighting the concentration of capital available for high-growth healthtech ventures.

Country	VC-Funding (EUR)	Inhabitants	VC per Capita (EUR)
Finland	2,200,000,000	5,621,739	391
Switzerland	3,100,000,000	9,007,798	344
United Kingdom	22,000,000,000	69,931,528	315
Ireland	1,600,000,000	5,356,950	299
Sweden	2,200,000,000	10,701,047	206
Denmark	1,200,000,000	6,023,520	199
Netherlands	3,300,000,000	18,448,775	179
Germany	7,700,000,000	83,644,258	92

The Robotics Renaissance in Interventional Medicine

At the forefront of the Swiss medtech revolution is a new generation of surgical robotics companies that leverage soft materials and magnetic control to overcome the physical limitations of traditional rigid instruments. These leaders are addressing high-stakes clinical scenarios, particularly neuro-vascular interventions and complex brain surgeries, where precision at the millimetre scale is non-negotiable.

1. NanoFlex Robotics: Magnetic Navigation for Neurovascular Health

NanoFlex Robotics, an ETH Zurich spin-off founded in 2021, represents a paradigm shift in the treatment of stroke and other neuro-vascular diseases. The company's technology is rooted in over 20 years of research from the Multi-Scale Robotics Lab, led by co-founder Bradley Nelson. Under the leadership of CEO Matt Curran, NanoFlex has developed a soft robotic system that enables surgeons to steer specially adapted catheters and guide wires through the intricate vasculature of the brain using remote magnetic fields.

The core innovation lies in the transition from manual, friction-dependent catheter manipulation to a magnetic steering system that minimises trauma to the vessel walls. This technology not only simplifies complex procedures but also potentially reduces the radiation exposure for physicians, as the system can be operated from a distance. In 2023, NanoFlex secured USD 12 million in Series A funding, which has facilitated the installation of their first demo systems and the progression toward first-in-human clinical trials.

2. Distalmotion: Democratising Robotic Surgery in Outpatient Settings

While giants like Intuitive Surgical dominate the hospital-based soft-tissue robotics market, Distalmotion has identified a critical underserved segment: the Ambulatory Surgery Center (ASC). Their DEXTER® Robotic Surgery System is designed for a high-volume, cost-effective environment, offering a smaller footprint and seamless integration into existing operating rooms.

Distalmotion, led by CEO Greg Roche, a medtech veteran with over 20 years of experience, successfully closed a USD 150 million Series G round in 2025. This was followed by a strategic investment from Johnson & Johnson Innovation in early 2026, aimed at accelerating the US adoption of DEXTER for general surgery, gynecology, and urology. The DEXTER system’s unique value proposition is its "hybrid" approach, allowing surgeons to switch between robotic and manual laparoscopic modes instantly, thereby optimizing clinical efficiency in outpatient settings.

3. Clee Medical: Advancing Real-Time Vision in Neurosurgery

Clee Medical addresses the "dynamic uncertainty" of the neurosurgical operating room. Traditional neurosurgery relies heavily on static, pre-operative imaging (MRI/CT), which does not account for the "brain shift" that occurs during surgery. Clee Medical’s flagship platform, Neuro Access, integrates ultra-high-resolution real time intra-operative Optical Coherence Tomography (OCT) imaging with AI-powered anatomical navigation.

The Geneva-based startup, emerging from the Wyss Center in 2024, is led by CEO Matt Lapinski, who brings extensive experience in building Class III medical device startups in the United States. In early 2026, the company raised seed funding to accelerate its clinical validation program, with the goal of making minimally invasive brain surgery safer and more scalable.

Leadership Profile: Surgical Robotics

Leader	Company	Background	Strategic Focus
Matt Curran	NanoFlex Robotics	University of Edinburgh; Medical device commercialization	Stroke treatment via magnetic soft robotics
Greg Roche	Distalmotion	Sociology and Law; 20+ years in MedTech (Stryker, etc.)	ASC expansion and purpose-built robotics
Matt Lapinski	Clee Medical	Engineer; Class III device expert (Medtronic background)	Real-time OCT imaging for neurosurgery

The Digitalisation of Diagnostics and Preventive Health

A major theme in the 2025–2026 cohort is the decentralization of clinical-grade diagnostics, moving specialized testing from centralized hospital labs directly to the point-of-care or even into the patient's home. This trend is powered by sophisticated AI algorithms that democratise expert-level interpretation of medical data.

4. QUMEA: Redefining Patient Safety with Radar-Based AI

QUMEA, the winner of the Swiss Medtech Award 2025, has become a benchmark for digital health implementation in institutional care. The company’s technology, developed under CEO Cyrill Gyger, utilizes a contactless 3D radar sensor to monitor patient movement patterns around the clock. Unlike camera-based systems, QUMEA’s approach is entirely anonymous, respecting patient privacy while using AI to analyse movement in real-time.

The clinical impact of the system is quantifiable: somatic hospitals implementing QUMEA have reported an average reduction in falls of 74%. This proactively preventative standard of care has led to broad implementation across over 130 institutions in the DACH region and the Nordics. In October 2025, the private equity firm GRO made a strategic investment in QUMEA to accelerate its international expansion, signalling the maturity of the company's business model.

5. Scanvio Medical: AI-Assisted Ultrasound for Endometriosis

Scanvio Medical is addressing one of the most significant diagnostic gaps in women's health: endometriosis. Currently, the average delay for an endometriosis diagnosis is 8 to 12 years, primarily because identifying the condition via ultrasound requires rare, high-level expertise. Scanvio, an ETH Zurich spin-off founded in 2024, is developing a real-time AI assistant that guides clinicians through standard pelvic ultrasound examinations to identify signs of the disease.

Led by CEO Stefan Tuchschmid—who previously scaled VirtaMed into a global leader in surgical training—Scanvio secured USD 3.4 million in a seed round in 2025. The platform leverages algorithms developed during CTO Dr. Fabian Laumer’s PhD research, aiming to democratise expert-level ultrasound diagnostics for gynaecology practices worldwide.

6. Testmate Health: Democratizing Sexual Health Testing

Testmate Health is positioned to tackle the "silent epidemic" of sexually transmitted infections (STIs) by providing a product aligned with urgent public health initiatives. Their diagnostic solution offers a low-barrier, rapid testing platform that can be used outside of traditional clinical settings, encouraging regular screening and faster treatment cycles. By combining molecular diagnostic accuracy with consumer-grade ease of use, Testmate Health represents the vanguard of "home-first" clinical diagnostics in Switzerland.

7. Avelo: Breath-Based Pathogen Collection

Avelo is revolutionizing the diagnosis of lower respiratory tract infections through its innovative breath collection device.Traditional methods for diagnosing pneumonia often involve invasive procedures or the collection of sputum, which can be difficult for many patients. Avelo’s hand-held device captures pathogens directly from a patient’s breath, enabling a non-invasive and rapid pathway to identifying the cause of infection. This technology is critical for antimicrobial stewardship, as it allows clinicians to differentiate between viral and bacterial infections at the point-of-care, ensuring that antibiotics are only prescribed when necessary.

8. IMAI MedTech: Automated 3D Histology

IMAI MedTech, a Schlieren-based startup founded in 2024 by CEO Francesca Catto and Robert Axelrod, is bringing three-dimensional visualisation to the field of pathology. Conventional histology relies on thin 2D slices of tissue, which can miss critical diagnostic markers and lead to misinterpretation. IMAI has developed an automated platform for fast tissue processing and 3D visualisation, vital for both clinical and research use in oncology diagnostics. The team, which includes CTO Sascha Brun, plans to use their CHF 150,000 Venture Kick award to finalise their hardware prototype and scale AI features for automated cell counting and cancer mass measurement.

Key Performance Indicators: Diagnostic Leaders

Startup	Metric	Impact/Result
QUMEA	Fall Reduction	74% average reduction in falls
Scanvio Medical	Diagnostic Delay	Aims to reduce 8-12 year wait for endometriosis
Evismo	Network	1,500+ specialists using remote diagnostics
IMAI MedTech	Market Size	Targeting USD 16B histology/cytology market

Neuro-technology and the Restoration of Sensation

The Swiss neuro-technology sector has moved beyond simple diagnostic tools toward therapeutic devices that interface directly with the nervous system to restore lost functions. These "bio-digital" leaders are combining material science with artificial intelligence to treat disorders ranging from epilepsy to peripheral neuropathy.

9. Neurosoft Bioelectronics: Soft Stretchable Brain Interfaces

Neurosoft Bioelectronics is pioneering the use of soft, stretchable materials for neural implants. Led by CEO and co-founder Dr. Nicolas Vachicouras, the company addresses the mismatch between rigid electronic electrodes and the soft tissue of the brain. In February 2025, Neurosoft achieved a major milestone with the successful testing of its high-channel-count interface in human patients during epilepsy surgery at University Medical Center Utrecht.

The company's primary focus is the restorative treatment of tinnitus, epilepsy, and other neurological disorders. In early 2026, Neurosoft entered a multiyear partnership with Science Corp, granting them access to a world-class clinical-grade neural engineering platform. This collaboration is expected to aggressively accelerate the clinical adoption and commercial scaling of their pioneering neural data platform.

10. MachineMD: Neuro-Ophthalmology via VR and Ocular Biomarkers

MachineMD, a Swiss-American medical device company based in Bern, is revolutionizing brain diagnostics using ocular biomarkers. Their platform, Neos, is a VR-based neurodiagnostic tool that enables fast, scalable, and non-invasive brain assessments by tracking eye movements. CEO Dominic Senn leads a team that includes medical director Mathias Abegg and CTO Dominik Brügger.

In October 2024, Neos became the first VR headset to obtain EU MDR Class IIa certification for the assessment and diagnosis of ophthalmic and neurological disorders. This certification is a significant enabler for precision medicine, supporting research and diagnosis for people with Parkinson's, multiple sclerosis (MS), and other rare diseases.MachineMD’s technology addresses the shortage of neuro-ophthalmologists by providing highly reproducible, objective data that can be interpreted by a wider range of healthcare professionals.

11. Mynerva: Tactile Restoration for Peripheral Neuropathy

Mynerva, an ETH Zurich spin-off, won the Venture Awards Grand Prize in June 2025 for its work in restoring the sense of touch. Led by CEO Greta Preatoni, the company focuses on medical technology for patients suffering from sensory loss, particularly those with diabetic peripheral neuropathy. By providing artificial tactile feedback, Mynerva’s technology helps patients regain balance and reduce the risk of falls, a critical complication of neurodegenerative diseases.

12. Biped Robotics: AI-Powered Mobility for the Visually Impaired

Biped Robotics has developed an AI-powered wearable that assists blind and visually impaired individuals in navigating safely in real time. The device uses 3D cameras and spatial audio to identify obstacles and provide directional guidance, essentially acting as a "co-pilot" for human mobility. Ranked 95th in the 2025 Top 100 Swiss Startup Award, Biped represents a broader trend of applying computer vision and edge-AI to enhance the quality of life for those with physical or sensory impairments.

Advanced Therapeutics, Vaccines and Bio-Engineering

The Swiss life sciences sector continues to push the boundaries of biotechnology, with a specific focus on antibacterial resistance, targeted drug delivery, and orthopedic restoration. These future leaders are leveraging synthetic biology and advanced material science to create treatments that were previously impossible.

13. Baxiva: Leading the Fight Against E. Coli

Baxiva, an ETH Zurich spin-off incorporated in 2025, is developing a first-in-class vaccine designed to prevent diseases caused by Escherichia coli (E. coli), such as urinary tract infections. Led by CEO Dr. Giorgia Greter and CSO Dr. Tim Keys, the company combinesScientific innovation in bacterial vaccines with industrial experience in conjugate development.

In early 2026, Baxiva joined the CARB-X portfolio, receiving USD 3 million to advance its vaccine candidates toward clinical development. Their multivalent glycoconjugate platform addresses a critical unmet need in infection prevention, offering a viable alternative to the overuse of antibiotics. Baxiva’s success highlights the power of Swiss glycobiology research in addressing global health threats like antimicrobial resistance.

14. Flowbone: Strengthening Bones with Injectable Hydrogels

Flowbone addresses the massive public health burden of osteoporosis through its injectable, "bone-seeding" gel. The technology, which provides a local strengthening of fragile bones, is designed to prevent fractures before they occur.Under the leadership of project leaders like Peyman Karami and Valérie Malfroy Camine, Flowbone exemplifies the trend toward "minimally invasive preventative orthopaedics," where early intervention can prevent the catastrophic consequences of hip and spinal fractures in the elderly population.

15. Positrigo: Decentralized Nuclear Imaging for Brain Health

Positrigo is democratizing advanced functional brain imaging through its ultra-compact PET system, NeuroLF. Founded in 2018 as an ETH Zurich spin-off by CEO Jannis Fischer and COO Max Ahnen, Positrigo aims to make precision brain scanning available to everyone at a fraction of today's cost.

In 2025, the company raised CHF 7 million in a round led by HealthCap to boost production and commercialization. In early 2026, Positrigo was named a finalist for the Swiss Medtech Award 2026. Their "BrainPET Accelerator Program," launched in the US in 2026, enables neurology practices to offer advanced PET imaging directly within their offices, significantly improving access to diagnostics for Alzheimer's disease and other neurodegenerative conditions.

16. Myria Biosciences: GEMMS for Transformative Small-Molecules

Myria Biosciences, led by CEO Steven Schmitt, is an ETH Zurich and HZI/HIPS spin-off that pioneers drug discovery through Genetically Engineered Modular Molecule Scaffolds (GEMMS). Their platform integrates high-throughput synthetic biology with AI-driven design to develop therapies that exceed the constraints of nature. Myria represents the "tech-bio" frontier, where synthetic natural products are smartly engineered for biological production, paving the way for next-generation small-molecule therapies.

Scientific Leadership Profile: Therapeutics and Bio-Engineering

Leader	Company	Domain Expertise	Core Innovation
Giorgia Greter	Baxiva	Microbiology/Vaccines	E. coli glycoconjugate vaccine platform
Steven Schmitt	Myria Biosciences	Synthetic Biology	GEMMS for AI-driven drug discovery
Jannis Fischer	Positrigo	Particle Physics (ETH PhD)	Compact NeuroLF PET system
Valérie Malfroy Camine	Flowbone	Orthopedic Bio-Engineering	Injectable "bone-seeding" hydrogel

Systems of Care and Structural Medtech Innovation

The final group of future leaders focuses on the hardware and software "infrastructure" of healthcare, optimising existing clinical workflows and improving the accuracy of standard surgical procedures.

17. Evismo: Intelligent Remote Diagnostics for the Heart

Evismo is a Zurich-based healthtech company that has combined state-of-the-art sensor technology with AI-based software to revolutionise remote cardiac diagnosis. A finalist for the Swiss Medtech Award 2025, Evismo provides a suite of diagnostic services: CardioFlex for cardiac arrhythmias, RespiFlex for sleep apnea, and StressCheck for analyzing stress and burnout. Their model facilitates early detection directly in the general practitioner's practice, ensuring that patients receive timely interventions before condition escalation.

18. Bonebridge: Quality-Driven Musculoskeletal Trauma Solutions

Bonebridge focuses on high product quality and ease of clinical application in the field of musculoskeletal trauma. As a finalist for the Swiss Medtech Award 2025, Bonebridge addresses various clinical challenges related to trauma surgery through innovative hardware and a focus on "Swissness" in manufacturing. Their collaborative approach with globally recognised partners ensures that their developments contribute sustainably to the improvement of patient care in high-stress surgical environments.

19. HeroSupport: Personalizing Radiotherapy with 3D Printing

HeroSupport, founded in 2023, specializes in patient-specific immobilization for radiation therapy. Their flagship product, VENUS SHELL, is a 3D-printed immobilization shell designed for breast radiotherapy in a prone position. This patient-specific approach ensures that the target tissue is precisely positioned during every treatment session, improving clinical outcomes and patient comfort. HeroSupport was awarded the "most investable startup" title at the Swiss-Italian Startup Award 2025, reflecting the high market interest in personalised oncology support tools.

20. PeriVision: AI-Driven Visual Function Assessment

PeriVision, ranked 69th in the 2025 Top 100 Swiss Startup Award, combines AI, VR, and cloud technology to build next-generation systems for understanding visual function. Their solution allows for the fast and objective assessment of the visual field, which is critical for monitoring chronic conditions like glaucoma. By utilising portable VR headsets, PeriVision enables testing outside of the traditional darkened clinical room, making diagnostic screening more accessible and efficient for both patients and providers.

The Future Roadmap for Swiss Medtech and HealthTech

As the Swiss ecosystem moves toward 2030, several macro-trends will define the success of these 20 leaders. The first is the integration of "Foundation Models" and "Multimodal AI" into clinical workflows. This involves combining electronic health records (EHR), medical imaging, and sensor data from wearables like those of QUMEA or feedback intuitive to provide a holistic, predictive view of patient health.

Secondly, the "Late-Stage Gap" will continue to drive M&A activity. The acquisitions of Araris Biotech for USD 1.1 billion and OBaris by Johnson & Johnson in 2025 serve as a powerful validation of the Swiss academic spin-off model, yet also highlight the reality that most Swiss high-tech ventures will ultimately be scaled by international giants.

Finally, the focus on "Modernizing the Mechanics of Care" will remain a priority. This includes the rollout of digital hospitals and smart infrastructure, such as the smart hospital platforms being developed by Stryker and others, which will serve as the host environment for many of the Swiss robotic and AI innovations discussed.

Anticipated Milestones (2026–2030)

Year	Company	Milestone Type	Description
2026	Positrigo	Award/Finalist	Swiss Medtech Award Ceremony (June 10, 2026)
2026	Clee Medical	Clinical	Initiation of first-in-human neurosurgery studies
2026	Distalmotion	Regulatory	Expected FDA gynecology/general surgery expansion
2026	Baxiva	Preclinical	Advance vaccine project toward clinical phase with CARB-X
2027	Roche	Regulatory	Planned filing for afimkibart (bowel disease)

Conclusion: Synthesising the 2025-2026 Swiss Leadership

The 20 future leaders profiled in this report represent a sophisticated synthesis of Switzerland’s long-standing excellence in precision engineering and its rapid ascent in the fields of artificial intelligence and biotechnology. The recurring theme across these companies, whether in the soft robotics of NanoFlex, the AI-diagnostics of Scanvio, or the glycobiology of Baxiva, is the translation of deep scientific insight into tangible patient benefit.

The robust support system provided by institutions like ETH Zurich, EPFL, Venturelab, and Venture Kick has created a uniquely reliable signal for global investors. While the path to global scale often leads through the United States, as evidenced by the 2025 Venture Leaders Medtech Boston roadshow, the intellectual and technological "Swissness" of these ventures remains their primary competitive advantage. By 2030, the innovations of these 20 companies are poised to be integrated into the standard of care worldwide, solidifying Switzerland’s position as a global epicentre for the future of healthcare.

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech